The Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Int J Mol Sci. 2023 Apr 6;24(7):6825. doi: 10.3390/ijms24076825.
Gene expression profiling (GEP) is clinically validated to stratify the risk of metastasis by assigning uveal melanoma (UM) patients to two highly prognostic molecular classes: class 1 (low metastatic risk) and class 2 (high metastatic risk). However, GEP requires intraocular tumor biopsy, which is limited by small tumor size and tumor heterogeneity; furthermore, there are small risks of retinal hemorrhage, bleeding, or tumor dissemination. Thus, ocular liquid biopsy has emerged as a less-invasive alternative. In this study, we seek to determine the aqueous humor (AH) proteome related to the advanced GEP class 2 using diagnostic AH liquid biopsy specimens. Twenty AH samples were collected from patients with UM, grouped by GEP classes. Protein expression levels of 1472 targets were analyzed, compared between GEP classes, and correlated with clinical features. Significant differentially expressed proteins (DEPs) were subjected to analysis for cellular pathway and upstream regulator identification. The results showed that 45 DEPs detected in the AH could differentiate GEP class 1 and 2 at diagnosis. IL1R and SPRY2 are potential upstream regulators for the 8/45 DEPs that contribute to metastasis-related pathways. AH liquid biopsy offers a new opportunity to determine metastatic potential for patients in the absence of tumor biopsy.
基因表达谱(GEP)已通过将葡萄膜黑色素瘤(UM)患者分为两个具有高度预后分子特征的类别来临床验证,用于转移风险分层:1 类(低转移风险)和 2 类(高转移风险)。然而,GEP 需要眼内肿瘤活检,这受到肿瘤体积小和肿瘤异质性的限制;此外,还有视网膜出血、出血或肿瘤扩散的小风险。因此,眼内液活检已成为一种侵袭性较小的替代方法。在这项研究中,我们旨在使用诊断性 AH 液体活检标本确定与先进 GEP 2 类相关的房水(AH)蛋白质组。从 UM 患者中收集了 20 个 AH 样本,按 GEP 分类分组。分析了 1472 个靶标蛋白的表达水平,比较了 GEP 分类之间的差异,并与临床特征相关。对显著差异表达的蛋白质(DEPs)进行了细胞途径和上游调节剂分析。结果表明,在 AH 中检测到的 45 个 DEP 可以在诊断时区分 GEP 1 类和 2 类。IL1R 和 SPRY2 是对 8/45 个 DEP 的潜在上游调节剂,这些 DEP 有助于与转移相关的途径。AH 液活检为没有肿瘤活检的患者提供了确定转移潜力的新机会。